10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics (Nasdaq: TXG) has announced the commercial shipping of its Chromium Single Cell Multiome ATAC + Gene Expression solution, the first product to simultaneously profile a cell's epigenome and transcriptome. This innovative approach enhances research capabilities by directly linking epigenetic programs to gene expression, improving understanding of cell functionality and disease mechanisms. Early adopters include Stanford and Mt. Sinai, emphasizing its potential in studying immune response to cancer and neuropsychiatric diseases.

10x Genomics, Inc. (NASDAQ: TXG) announced a public offering of 4,000,000 shares of its Class A common stock, priced at $110.00 each. An additional 600,000 shares may be purchased by underwriters. The offering is expected to close on September 15, 2020, pending customary closing conditions. The underwriting group consists of J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company, with Stifel and William Blair as co-managers. This offering aims to strengthen the company's capital position.

10x Genomics (NASDAQ: TXG) announced a public offering of 3,500,000 shares of its Class A common stock. The offering is underwritten by J.P. Morgan, BofA Securities, and Cowen and Company, with a 30-day option for underwriters to purchase an additional 525,000 shares. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning shares cannot be sold until it is approved. The company aims to raise capital for ongoing business operations.

10x Genomics (Nasdaq: TXG) will participate in the Morgan Stanley Virtual Healthcare Conference on September 16, 2020. Management is scheduled for a fireside chat at 8:45 a.m. PT / 11:45 a.m. ET. Interested parties can access the live and archived webcast on the company's investors' section of its website.

10x Genomics specializes in life science technology, providing integrated solutions to analyze biological systems. Its products are utilized by the majority of leading research institutions and pharmaceutical companies worldwide.

10x Genomics (Nasdaq: TXG) will participate in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit on August 12, 2020, at 8:00 a.m. PT / 11:00 a.m. ET. The management team will engage in a fireside chat, which can be accessed via a live and archived webcast on the company’s investor website.

10x Genomics is dedicated to advancing human health through its innovative life science technologies, which include instruments, consumables, and software for biological analysis. Their solutions are widely adopted in top research institutions and pharmaceutical companies.

10x Genomics (TXG) announces the launch of its Chromium Single Cell Immune Profiling v2, enhancing research in immunology, oncology, and infectious diseases, including COVID-19. This product improves gene detection sensitivity by up to 60%, enabling researchers to profile thousands of genes at single-cell resolution cost-effectively. Key features include characterizing immune cell diversity and analyzing disease progression. The product is available for pre-order, with shipping expected by month's end.

10x Genomics (TXG) will report its Q2 2020 financial results on August 11, 2020, after market close. A conference call will take place at 1:30 p.m. PT to discuss the results and company outlook. The webcast will be accessible via the company's website and archived for 45 days. 10x Genomics specializes in life science technology, offering integrated solutions that analyze biological systems. The company has been widely adopted by leading research institutions and pharmaceutical companies, with over 740 patents in its portfolio.

10x Genomics (Nasdaq: TXG) has launched its Visium Clinical Translational Research Network (CTRN), selecting 45 members from 185 applications. This initiative aims to enhance research in oncology, immuno-oncology, and other fields by improving workflows in clinical translational research. Members will gain access to a collaborative community, significant discounts, and specialized support related to the Visium platform. The network connects researchers across 39 global institutions, promoting advancements in studies such as tumor response and spatial gene expression.

10x Genomics (TXG) reported a revenue of $71.9 million for Q1 2020, marking a 34% increase from Q1 2019. The company noted a gross margin of 79%, an improvement from 74% the previous year, due to lower accrued royalties. However, operating expenses rose by 80% to $76.7 million, leading to an operating loss of $19.9 million, compared to $3.0 million in the same quarter last year. Notably, 10x Genomics withdrew its 2020 revenue guidance due to uncertainties tied to the COVID-19 pandemic.